More than $104 billion is spent annually in the United States on cancer care, or 5% of all spending for health care. Currently, there are approximately 2 million men with prostate cancer (PCa). In 2006, the National Cancer Institute attributed $9.9 billion in total medical expenditures to PCa compared with $13.9 billion for breast cancer, $12.2 billion for colorectal cancer, $10.3 billion for lung cancer, and $10.2 billion for lymphoma. For PCa, $3.92 billion was spent on initial care (39.7%), $5.03 billion on continuing care (51%), and $918 million in the last year of life (9.3%). For those with metastatic disease, 50% of the total lifetime costs of treating PCa may occur in the last year of life.
This article reviews costs of care for PCa, from initial treatment to metastatic and castration-resistant disease, recognizing that few clinical trials have included economic assessments of managing the disease.
This activity has been designed to meet the educational needs of urologists and other clinicians involved in the treatment of patients with prostate cancer.
After completing the activity, the participant should be better able to:
- Describe the costs of prostate cancer from diagnosis to treatment, including current and emerging therapies for castration-resistant prostate cancer
- Explain the rationale for selection of androgen deprivation therapy for patients with advanced prostate cancer based on delivery route, adverse effects, and quality of life
- Describe Medicare reimbursement coverage and coding (Parts B and D) and considerations in the patient’s ability to co-pay for medications to ensure treatment adherence
STATEMENT OF NEED:
Urologists and other clinicians who provide care for men with prostate cancer require education focusing on the costs of care for prostate cancer, from diagnosis to treatment, including androgen deprivation therapy and consideration of adverse events, quality of life, and a patient’s financial situation, to help them provide optimal, rational, and compassionate care to their patients with advanced prostate cancer.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Haymarket Media, Inc. MER is accredited by the ACCME to provide continuing medical education for physicians.
Medical Education Resources designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit���. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE for Nurses
Medical Education Resources is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This CE activity provides 1.00 contact hour of continuing nursing education.
Medical Education Resources is a provider of continuing nursing education by the California Board of Registered Nursing, Provider #CEP 12299, for 1.00 contact hour.
Daniel P. Petrylak, MD
Professor of Medicine and Program Director
Genitourinary Oncology Section
Division of Hematology/Oncology
Co-Leader, Prostate Cancer
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, NY
Disclosure of Conflicts of Interest
Medical Education Resources ensures balance, independence, objectivity, and scientific rigor in all our educational programs. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure all scientific research referred to, reported, or used in a CME activity conforms to the generally accepted standards of experimental design, data collection, and analysis. MER is committed to providing its learners with high-quality CME activities that promote improvements or quality in health care and not a commercial interest.
The faculty reported the following financial relationships with commercial interests whose products or services may be mentioned in this CME activity:
Daniel P. Petrylak, MD
Advisory Board/Consultant: Amgen, Novartis Otsuka, Egenix (Chair, Scientific Advisory Board), Bellicum, Ferring, AstraZeneca, Johnson and Johnson, Dendreon, Millennium. Research Support: Progenics, Celgene, Sanofi Aventis, Dendreon, Pfizer, GlaxoSmithKline, Boehringer Ingelheim, Medivation, Eisai, Abbott, Johnson and Johnson. Board Member: Prostate Cancer Education Council.
Publishing Staff Disclosures
The content managers, Debra A. Hughes, Mary Jo Krey, Jody A. Charnow, and Marina Galanakis of Haymarket Medical Education, and Julie Johnson, PharmD, and Veronda Smith, BC-FNP, of Medical Education Resources, have disclosed that they have no relevant financial relationships or conflicts of interest relating directly or indirectly to this activity.
Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Medical Education Resources, Inc. (MER), and Haymarket Medical Education (HME) do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of MER and HME. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of Abbott Laboratories, Medical Education Resources or Haymarket Media, Inc. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Abbott Laboratories, Medical Education Resources, or Haymarket Media, Inc. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.
This activity is jointly sponsored by Medical Education Resources and Haymarket Medical Education.
This activity is supported by an educational grant from Abbott Laboratories.
If you have any questions relating to the accreditation of this activity, please contact:
Medical Education Resources, Inc.
1500 West Canal Court
Littleton, CO 80120-5615
To obtain credit, a post-test score of 70% or better is required. This CME is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test survey, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.
WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution
set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.
MACINTOSH® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20
MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands
of Colors”; Macromedia Flash Player 6 or higher.